Evidence map›Paper›PMID 34516619›Full record

ArticleEuropean heart journal. Cardiovascular Imaging2022

Optimal echocardiographic assessment of myocardial dysfunction for arrhythmic risk stratification in phospholamban mutation carriers.

Karim Taha, Tom E Verstraelen, Remco de Brouwer, Rianne H A C M de Bruin-Bon, Maarten J Cramer, Wouter P Te Rijdt, Berto J Bouma, Rudolf A de Boer, Pieter A Doevendans, Folkert W Asselbergs and 3 more

Open access · hybridAbstract read
In one paragraph

Article in European heart journal. Cardiovascular Imaging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Karim TahaDepartment of Cardiology, University Medical Center Utrecht, Utrecht, TheNetherlands.ORCID 0000-0001-6508-5461
Tom E VerstraelenHeart Center, Department of Cardiology, Amsterdam University Medical Center, Location Academic Medical Center, Amsterdam, TheNetherlands.
Remco de BrouwerDepartment of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, TheNetherlands.ORCID 0000-0002-5705-2034
Rianne H A C M de Bruin-BonHeart Center, Department of Cardiology, Amsterdam University Medical Center, Location Academic Medical Center, Amsterdam, TheNetherlands.
Maarten J CramerDepartment of Cardiology, University Medical Center Utrecht, Utrecht, TheNetherlands.
Wouter P Te RijdtNetherlands Heart Institute, Utrecht, TheNetherlands.
Berto J BoumaHeart Center, Department of Cardiology, Amsterdam University Medical Center, Location Academic Medical Center, Amsterdam, TheNetherlands.
Rudolf A de BoerDepartment of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, TheNetherlands.
Pieter A DoevendansDepartment of Cardiology, University Medical Center Utrecht, Utrecht, TheNetherlands.
Folkert W AsselbergsDepartment of Cardiology, University Medical Center Utrecht, Utrecht, TheNetherlands.
Arthur A M WildeHeart Center, Department of Cardiology, Amsterdam University Medical Center, Location Academic Medical Center, Amsterdam, TheNetherlands.
Maarten P van den BergDepartment of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, TheNetherlands.
Arco J TeskeDepartment of Cardiology, University Medical Center Utrecht, Utrecht, TheNetherlands.
University Medical Center Utrecht · NLAmsterdam UMC Location University of Amsterdam · NLUniversity Medical Center Groningen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsPhospholamban (PLN) p.Arg14del mutation carriers are at risk of developing malignant ventricular arrhythmias (VAs) and/or heart failure. Currently, left ventricular ejection fraction (LVEF) plays an important role in risk assessment for VA in these individuals. We aimed to study the incremental prognostic value of left ventricular mechanical dispersion (LVMD) by echocardiographic deformation imaging for prediction of sustained VA in PLN p.Arg14del mutation carriers. METHODS AND

resultsWe included 243 PLN p.Arg14del mutation carriers, which were classified into three groups according to the '45/45' rule: (i) normal left ventricular (LV) function, defined as preserved LVEF ≥45% with normal LVMD ≤45 ms (n = 139), (ii) mechanical LV dysfunction, defined as preserved LVEF ≥45% with abnormal LVMD >45 ms (n = 63), and (iii) overt LV dysfunction, defined as reduced LVEF <45% (n = 41). During a median follow-up of 3.3 (interquartile range 1.8-6.0) years, sustained VA occurred in 35 individuals. The negative predictive value of having normal LV function at baseline was 99% [95% confidence interval (CI): 92-100%] for developing sustained VA. The positive predictive value of mechanical LV dysfunction was 20% (95% CI: 15-27%). Mechanical LV dysfunction was an independent predictor of sustained VA in multivariable analysis [hazard ratio adjusted for VA history: 20.48 (95% CI: 2.57-162.84)].

conclusionLVMD has incremental prognostic value on top of LVEF in PLN p.Arg14del mutation carriers, particularly in those with preserved LVEF. The '45/45' rule is a practical approach to echocardiographic risk stratification in this challenging group of patients. This approach may also have added value in other diseases where LVEF deterioration is a relative late marker of myocardial dysfunction.

Indexed as

CardiomyopathiesVentricular Dysfunction, LeftEchocardiographyHumansMutationPhospholambanRisk AssessmentStroke VolumeVentricular Function, LeftPhospholambandeformation imaginggenetic cardiomyopathymechanical dispersionphospholambanrisk stratificationventricular arrhythmia

Identifiers

PMID34516619
PMCPMC9584619
OpenAlexW3200197850

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.